ArticleBMC infectious diseases2025
Xenomonitoring as an epidemiological tool supporting post-stop surveillance of albendazole-ivermectin mass drug distribution in the Bougouni-Yanfolila evaluation unit, Sikasso, Mali, in 2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMali and Guinea share a border and are both endemic for lymphatic filariasis (LF). However, their progress towards eliminating this disease varies. Mali is currently in the LF transmission assessment survey phase (TAS), while Guinea continues to implement mass drug administration (MDA). As the populations of these two countries are closely related, and vectors are present, the emergence of LF is theoretically possible in the Bougouni-Yanfolila evaluation unit (EU). This XenoFil study, which combines xenomonitoring and serosurveillance in health facilities, was used as a surveillance tool to assess LF transmission. The aim is to detect the emergence of LF in cross-border areas within the Bougouni-Yanfolila EU, after the third LF transmission assessment survey (TAS3).
methodIn the Bougouni-Yanfolila EU, we conducted a cross-sectional study to collect mosquitoes in the villages and blood samples from 6 years old and above (≥ 6 years old). In June, August 2022, and January 2023, we conducted three entomological studies in two ecologically distinct villages. The Ifakara type C tent trap (IFAKARA), the gravid trap, and indoor Pyrethrum spray catches were used to collect mosquitoes. For qPCR, mosquito of the same species was sorted into pools of twenty for molecular analysis using qPCR. The infection rate / the parasite prevalence was generated by the PoolScreen
resultsIn. the two study villages, we collected a total of 4,732 mosquitoes, of which 989 belonged to the species Anopheles gambiae s.l. and 3,743 to species of the genus Culex sp. A total of 264 pools were formed, with the genus Culex spp. accounted for 79.92% (211/264), while the genus Anopheles represented 20.08% (53/264). In June 2022, only one pool (0.53%) of Culex spp. tested positive [95% CI: 0.01-2.89]. Positive Anopheles pools were absent. The blood of ten of the 2056 individuals had positive results [0.49% (10/2056)]. Among the positives, one belonged to 6-7 years, two to that of 8-17 years, and seven to that of 18 years and older. Of the positive volunteers, 0.6% (6/996) were from Yanfolila's border health region. The average cost of XenoFil (entomology combined with serology) is 5,656,244 CFA francs (US$9070), and TAS has an average cost of 6,366,450 CFA francs (US$10209) in a survey conducted in one evaluation unit.
conclusionsThe new XenoFil approach proved to be an easy, effective, and relatively cheaper method for integrated LF surveillance in rural areas. From the perspective of integrated LF monitoring, XenoFil is needed for scaling up to other EU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.